Navigation Links
Elsevier Launches New Open Access Journal: Translational Proteomics

GENEVA, Switzerland, May 27, 2013 /PRNewswire/ --

First articles now available online on ScienceDirect

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce the launch of Translational Proteomics, an online-only, open access journal devoted to transferring fundamental discoveries in the field of proteomics to clinical applications, accelerating understanding and treatment of human diseases.

Jean-Charles Sanchez , Associate Professor at the University of Geneva, Head of the Biomedical Research Proteomics Group and Director of the Proteomics Core Facility of the Faculty of Medicine, will serve as Editor-in-Chief. The journal aims to cover all areas of research in human proteomics using multi-disciplinary approaches to untangle complex disease processes, such as oncology, neurology, immunology, cardiovascular diseases, infectious diseases and any internal medical disorder. Special sections within the journal will highlight research in areas like systems biology and integrative bioinformatics, clinical proteomics and personalized medicine, comparative proteomics and drug development, medical bioinformatics and biostatistics, food and health.

"With the launch of Translational Proteomics, we want to help the scientific and medical communities overcome the challenges they face on the long path from basic research to patient care," said Professor Sanchez. "By focusing on connecting basic proteomics research to ultimate clinical applications, the journal will provide a space for publications detailing proteomics experiments, from early discovery to validation and the bedside."

"We are excited about the launch of Translational Proteomics", added Dolors Alsina, Executive Publisher at Elsevier. "This journal provides a unique platform for the publication of high-quality, multi-disciplinary studies, combining research which, until now, would have been broken into two or more specialized publications."

For more information or to submit an article, visit

Open Access Publishing at Elsevier

Elsevier has been providing open access publishing options since 2005. Today, researchers can choose to publish in over 1,500 hybrid journals as well as 39 full open access journals and these numbers will continue to grow rapidly. All of Elsevier's open access publications have been peer reviewed, ensuring that the broader community not only reads the latest research but that it is factual, original and of the highest quality and ethical standards. For more information about Elsevier's open access program, visit

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.

Media contact
Kristian Wilson

SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
2. Elsevier / MEDai Appoints Tom Zajac as New President
3. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
4. Elsevier and Federation of Biochemical Societies Launch New Journal: FEBS Open Bio
5. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
6. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
7. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform:
8. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
9. Elsevier/Gold Standard Exclusive Publisher of New Predictive Drug Price Type
10. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
11. Elsevier Launches New Journal: Learning, Culture and Social Interaction
Post Your Comments:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
(Date:3/21/2016)... Massachusetts , March 22, 2016 ... facial recognition with passcodes for superior security   ... ), a leading provider of secure digital communications services, ... their biometric technology and offer enterprise customers, particularly those ... secure facial recognition and voice authentication within a mobile ...
Breaking Biology News(10 mins):